阿德福韦的结局附加的长达5年拉米夫定抢救治疗的患者拉米

StephenW

Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B
Authors

    First published: 30 December 2015Full publication history
    DOI: 10.1111/jgh.13046View/save citation
    Cited by: 1 article

    Funding Information

    Conflict of interest: All authors have nothing to declare.

Abstract
Background and Aim:

We investigated the long-term efficacy of adefovir add-on lamivudine rescue therapy in lamivudine-resistant chronic hepatitis B and the optimal cutoff hepatitis B virus (HBV) DNA level that predicts complete virological response (CVR) among patients without CVR after 1 year of treatment.
Methods:

We reviewed 167 lamivudine-resistant chronic hepatitis B patients who received adefovir add-on rescue therapy for up to 5 years. Multivariate analysis, area under the receiver operating characteristic curves, and Youden index were used.
Results:

Median age was 47.0 years; 112 patients were male. Median baseline HBV DNA level was 6.6 log10 IU/mL; hepatitis B e antigen was positive in 130 (77.4%) patients. Five-year CVR, alanine aminotransferase normalization, hepatitis B e antigen seroconversion, and adefovir resistance rates were 86.9%, 92.5%, 16.7%, and 6.0%, respectively. One-year HBV DNA level independently associated with CVR. Optimal cutoff HBV DNA level to predict CVR among patients who failed to achieve CVR at 1 year was 800 IU/mL (area under receiver operating characteristic curve 0.752; sensitivity 49.3%, specificity 93.5%). During the 5-year treatment, 92.1% of patients with favorable response (HBV DNA < 800 IU/mL at 1 year) achieved CVR; 45.6% achieved CVR among suboptimal responders (HBV DNA ≥ 800 IU/mL at 1 year) (P < 0.001).
Conclusion:

Complete virological response or HBV DNA level < 800 IU/mL after 1 year adefovir add-on lamivudine rescue therapy can favorably predict CVR.

StephenW

阿德福韦的结局附加的长达5年拉米夫定抢救治疗的患者拉米夫定耐药的慢性乙型肝炎
作者

    首次出版：12月30日公布2015Full历史
    DOI：10.1111 / jgh.13046View /保存引文
    1条：由引

    资金的信息

    利益冲突：所有作者没有东西申报。

抽象
背景与目的：

我们研究了阿德福韦的长期疗效附加在拉米夫定耐药的慢性乙型肝炎的最佳临界乙型肝炎病毒（HBV）DNA水平拉米夫定抢救治疗的1年后预测患者的完全病毒学应答（CVR）无CVR治疗。
方法：

我们回顾谁收到阿德福韦附加抢救治​​疗长达5年的167拉米夫定耐药的慢性乙肝患者。多变量分析中，受试者工作特征曲线下面积，以及约登指数使用。
结果：

平均年龄为47.0岁; 112例患者为男性。位基线HBV DNA水平为6.6 log10的国际单位/毫升;乙肝e抗原是130（77.4％）患者阳性。五CVR，谷丙转氨酶正常化，乙型肝炎e抗原血清学转换，和阿德福韦耐药率分别为86.9％，92.5％，16.7％和6.0％，分别为。一年HBV DNA水平与独立有关的CVR。最佳临界HBV DNA水平来预测CVR谁没有1年实现CVR患者为800国际单位/毫升（下ROC曲线0.752区;灵敏度49.3％，特异性为93.5％）。在5年的治疗，患者的（HBV DNA <800 IU / mL的1年）取得CVR反应良好92.1％; 45.6％达到CVR次优应答者（HBV DNA≥800 IU / mL的1年）（P <0.001）。
结论：

完整的病毒学应答或HBV DNA水平<800 IU / mL的1年后阿德福韦附加拉米夫定抢救治疗可以从优预测CVR。